Work

State of the Art Treatment of Triple Negative Breast Cancer

Year: 2011

Type: article

Abstract: Triple Negative Breast Cancer (TNBC) is characterized by negative staining for estrogen and progesterone receptors and a negative assay for HER2. TNBC is typically high grade and is characterized by genomic instability. It is commonly associated with a variety of other immunohistochemical features such as overexpression of EGFR and basal cytokeratins. It is clear, however, that TNBC is not a single disease entity, but is remarkably heterogeneous. However, it remains uncertain as to how this heterogeneity should affect treatment decisions.

Source: The Breast

DOI: 10.1016/j.breast.2011.08.016

Authors: Eric P. Winer, Nancy U. Lin

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,200